Carly Simpson
Papers
1
Total Citations
22
H-Index
1
About
Carly Simpson is a leading figure in the application of acoustic droplet ejection (ADE) technology for high-throughput cell-based assays, with her most-cited work, "Implementation and Challenges of Direct Acoustic Dosing into Cell-Based Assays" (2015, 22 citations), serving as a cornerstone reference in the field. Her research focuses on the practical integration and optimization of Labcyte Echo ADE systems within pharmaceutical R&D, particularly at AstraZeneca, where she has driven the global adoption of this method for compound dosing. Simpson’s major contribution lies in systematically addressing the unique challenges of direct acoustic dosing into live-cell assays—such as evaporation, cell stress, and assay compatibility—thereby enabling more precise, miniaturized, and high-throughput screening workflows. Her work has significantly reduced reagent consumption and improved data quality in drug discovery. Beyond this paper, Simpson has been instrumental in establishing best practices for ADE implementation across multiple therapeutic areas, influencing both academic and industrial laboratories. Her achievements underscore her role as a key innovator in assay miniaturization and automation, making her a vital resource for researchers seeking to leverage acoustic technology for cell-based applications.
Research Focus
Key Achievements
Top Papers
- 1